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Abstract
AIM: To evaluate the clinicopathological features of 
colorectal cancer (CRC) with a v-Raf murine sarcoma 
viral oncogene homolog B1 (BRAF ) mutation and its 
molecular interaction with microsatellite instability (MSI) 
and v-Ki-ras2 Kirsten rat sarcoma viral oncogene ho-
molog (KRAS) in patients with advanced CRCs.
METHODS: From October 2009 to December 2011, 
141 patients with stage Ⅲ (n  = 51) or Ⅳ (n  = 90) 
CRCs who were tested for the BRAF  mutation at Sever-
ance Hospital were included. Among 141 patients, five 
were excluded due to follow-up loss. Therefore, 136 
patients were included in the study. The clinicopatho-
logical data, MSI status, and KRAS/BRAF  mutation sta-
tus were reviewed retrospectively. In addition, to eval-
uating the value of BRAF  mutation status, progression-
free survival and overall survival in all patients were 
collected and compared between the BRAF  wild-type 
group and BRAF  mutation group.
RESULTS: Of 136 patients, 80 (58.8%) were male 
and the mean age was 59 years. BRAF  and KRAS  
mutations were detected in 9.6% and 35.3% of pa-
tients, respectively. Only 4.3% of patients had MSI-
high tumors and there were no MSI-high in tumors 
with a BRAF mutation. BRAF  mutations tended to be 
more frequent in stage Ⅳ than in stage Ⅲ (11.76% 
vs  5.88%, P  = 0.370). Patients with a BRAF  mutation 
had a lower incidence of KRAS  mutation than those 
without (7.69% vs  38.21%, P  = 0.033). Overall sur-
vival was significantly shorter in the BRAF  mutation 
group than in the BRAF  wild-type group both by uni-
variate analysis (P  = 0.041) and multivariate analysis 
(HR = 2.195; 95%CI: 1.039-4.640; P  = 0.039), while 
progression-free survival was not different according 
to BRAF  mutation status.
CONCLUSION: CRCs with a BRAF  mutation have dis-
tinct molecular features and resulted in a poor progno-
sis in Korean patients with advanced CRC.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
Key words: BRAF ; Colorectal cancer; Molecular fea-
tures; Chemotherapy response; Prognosis
Core tip: This study identified the clinicopathological 
features of colorectal cancer (CRC) with BRAF  muta-
tion and its molecular interaction with microsatellite in-
stability and KRAS  targeting only to stage Ⅲ/Ⅳ CRCs. 
These molecular markers enable the classification of 
CRCs into meaningful subtypes for prognosis. Our data 
strongly support the prognostic role of BRAF  mutation 
in Korean patients with advanced CRC.
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INTRODUCTION
Colorectal cancer (CRC) is the third most common can-
cer in Western countries. In Korea, CRC is the second 
most common cancer in males and the third in females, 
with an estimated 25782 new cases and 7645 deaths each 
year[1]. TNM staging of  CRC has become a promising 
tool in determining treatment and prognosis, but it is 
evident that CRC has a significant clinical heterogeneity 
even within the same pathologic stage[2-4]. Recent ad-
vances in molecular genetics enable the classification of  
CRC using molecular markers, including microsatellite 
instability (MSI) and v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS) and v-raf  murine sarcoma 
viral oncogene homolog B1 (BRAF) mutations, to pre-
dict prognosis and treatment response[5-8].
BRAF is a part of  the Ras/Raf/mitogen-activated 
protein kinase kinase (MAP2K)/mitogen-activated pro-
tein kinases (MAPK) signaling pathway. Many of  the 
transcription factors activated by the Ras/Raf/MAP2K/
MAPK pathway are involved in cell proliferation and 
differentiation and many growth factor genes have bind-
ing sites for transcription factors activated by the Ras–
ERK pathway, located in their promoter regions. Thus, 
aberrant activation of  this pathway may provoke self-
sufficiency in proliferative signals and continuous stimu-
lation of  cell growth[9]. Mutations of  KRAS or BRAF 
activate this pathway and are an established mechanism 
that drives colorectal carcinogenesis[10]. The most com-
mon mutation of  BRAF is the classic GTG-GAG substi-
tution at position 1799 of  exon 15, which results in the 
V600E amino acid change and the subsequent constitu-
tive activation of  the EGFR signaling pathway. Gener-
ally, 10% to 20% of  CRCs have BRAF mutations, and 
the incidence of  BRAF mutation varies according to 
the status of  the MSI. It has been reported that 34% to 
70% of  CRCs classified as MSI-high have BRAF muta-
tions[11-13]. Compared to KRAS mutations, patients with 
CRC and BRAF mutations show some different clinical 
manifestations. It is well known that CRCs with KRAS 
mutations respond poorly to cetuximab[14]. However, 
the predictive role of  BRAF mutations in response to 
cetuximab is not yet clear. As for prognostic markers, 
CRC with BRAF mutations have been shown to have 
significantly poor prognosis compared to those with BRAF 
wild-type[15-17], while KRAS mutations have no prognos-
tic role[18].
Although CRCs have rapidly increased in Korea, the 
incidence of  BRAF mutation and its clinical meaning 
have not yet been explored in Korean patients with CRC. 
The aim of  this study was to evaluate the clinicopatho-
logical features of  CRC with a BRAF mutation and its 
molecular interaction with MSI and KRAS mutation sta-
tus in patients with stage Ⅲ or Ⅳ CRC.
MATERIALS AND METHODS
From October 2009 to December 2011, 141 patients in 
stage Ⅲ (n = 51) and Ⅳ (n = 90) CRC underwent mo-
lecular testing, including MSI analysis and determination 
of  KRAS and BRAF mutation status in Severance Hos-
pital. Among the 141 patients, five were excluded due to 
follow-up loss. In total, 136 patients were included in the 
present study. After an initial staging work-up including 
a CT scan, patients without metastasis or with resectable 
liver or lung metastasis received surgery and adjuvant 
chemotherapy with FOLFOX. Patients with unresect-
able metastatic disease received palliative chemotherapy 
with FOLFOX or FOLFIRI[19,20]. The clinicopatho-
logical data, including age, sex, family history of  CRC, 
BMI (body mass index), Eastern Cooperative Oncology 
Group (ECOG) performance status tumor stage, tumor 
location, tumor grade, initial CEA and chemotherapeutic 
regimen were reviewed retrospectively. This study was 
approved by the Institutional Review Boards of  Yonsei 
University College of  Medicine.
DNA extract, MSI analysis, BRAF and KRAS sequencing
Before obtaining tissue samples, written informed con-
sent was obtained from all patients. Tissue samples from 
the tumor and normal colonic mucosa were obtained 
from each patient after resection. DNA extracted from 
each tumor was amplified by a standard polymerase 
chain reaction using five Bethesda guidelines panel loci 
(BAT25, BAT26, MFD15, D2S123, and D5S346)[21]. In 
accordance with the consensus definitions of  the Na-
tional Cancer Institute, tumor samples were classified as 
displaying high-degree microsatellite instability (MSI-H, 
instability at 30% or more of  the markers tested), low-
degree microsatellite instability (MSI-L, instability at 
less than 30% of  the markers tested), or microsatellite 
stability (MSS, stability at all of  the markers tested). Due 
to the similar biological properties between MSI-L and 
MSS, these two molecular phenotypes were grouped to-
gether in all analyses.
KRAS and BRAF were charged at ISU ABXI (Seoul, 
South Korea). Genomic DNA was extracted from 
10-μm-thick paraffin sections containing a portion of  
tumor tissue by the QIAamp DNA Mini kit (Qiagen, 
Hilden, Germany). Fifty nanograms of  DNA were am-
plified in a 20 μL reaction solution containing 10 μL 
of  2 X concentrated HotStarTaq Master Mix (Qiagen, 
Hilden, Germany), including polymerase chain reac-
tion (PCR) buffer with 3 mmol/L MgCl2, 400 μmol/L 
of  each dNTP, and 0.3 μmol/L of  each primer pair 
(KRAS F: 5’-ttatgtgtgacatgttctaat, R: 5’-agaatggtcctg-
caccagtaa/BRAF, F: 5’-atgcttgctctgataggaaaatga, R: 5’
-agcagcatctcagggcca). Amplifications were performed 
using a 15-min initial denaturation at 95 ℃, followed 
by 35 cycles of  30 s at 94 ℃, 30 s at 59 ℃, and 30 s 
at 72 ℃, and a 10-min final extension at 72 ℃. PCR 
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Table 1  Baseline characteristics of enrolled patients  n  (%)
products separated in 2% gel were purified with a QIA-
gen gel extraction kit (Qiagen). DNA templates were 
processed for the DNA sequencing reaction using the 
ABI-PRISM BigDye Terminator version 3.1 (Applied 
Biosystems, Foster City, CA, United States) with both 
forward and reverse sequence-specific primers. Twenty 
nanograms of  purified PCR products were used in a 
10 μL sequencing reaction solution containing 1 μL of  
BigDye Terminator v3.1 and 0.1 μmol/L of  the same 
PCR primer. Sequencing reactions were performed us-
ing 25 cycles of  10 s at 96 ℃, 5 s at 50 ℃, and 4 min 
at 60 ℃. Sequence data were generated with the ABI 
PRISM 3730 DNA Analyzer (Applied Biosystems) and 
analyzed by Sequencing Analysis 5.1.1. software (Applied 
Biosystems) to compare variations.
Statistical analysis
The primary outcome was to compare overall survival 
(OS) and progression-free survival (PFS) of  patients 
with BRAF mutation to those with BRAF wild-type. The 
secondary outcome was to evaluate the gene-gene inter-
action between BRAF mutation and KRAS mutation or 
MSI. Continuous variables were expressed as mean ± 
SD. Each patient’s baseline characteristics were analyzed 
by descriptive statistics. OS was calculated from the 
time of  diagnosis until death or the last follow-up visit, 
and PFS was calculated from the time of  diagnosis until 
disease recurrence or progression. OS and PFS were 
analyzed using the Kaplan-Meier method, and survival 
curves were compared using the log-rank method. Cox 
proportional hazards modeling was used to control mul-
tiple risk factors that have been shown to influence CRC 
survival by computing 95% confidence intervals (CIs). A 
P-value < 0.05 was considered statistically significant. All 
statistical analyses were performed using SPSS version 
18.0 (SPSS Inc., Chicago, IL, United States).
RESULTS
Patient characteristics
Of  136 patients, 107 (78.7%) patients were diagnosed 
with colon cancer and 29 (21.3%) with rectal cancer. 
Fifty-one (37.5%) patients were stage Ⅲ and 85 (62.5%) 
were stage Ⅳ. Thirteen patients (9.6%) had BRAF mu-
tations, and 48 (35.3%) patients had KRAS mutations. 
The most frequent mutation at KRAS was G12D, which 
accounted for 29.2% of  KRAS mutations (14/48). The 
second most frequent mutation was G13D (12/48), and 
the remainder occurred in the following order: G12V 
(9/48), G12C (6/48), G12S (4/48), G13C (2/48) and 
G12A (1/48). Five (4.3%) patients had MSI-high tu-
mors. Molecular characteristics such as MSI status and 
KRAS and BRAF mutation status were not significantly 
different according to the tumor location.
The clinicopathological characteristics of  patients ac-
cording to BRAF mutation are summarized in Table 1. 
Tumors with BRAF wild-type tended to exhibit more 
differentiated histology (91.9% vs 76.9%, P = 0.211) and 
an earlier stage (stage Ⅲ, 39.0% vs 23.1%; P = 0.370) than 
tumors with BRAF mutation. There was no MSI-H in tu-
mors with BRAF mutation. Tumors with BRAF wild-type 
had significantly more KRAS mutations than tumors with 
BRAF mutation (38.2% vs 7.7%, P = 0.033). Only one 
(7.7%) tumor with BRAF mutation had KRAS mutation. 
The other clinicopathological findings, such as sex, age, 
BMI, family history of  CRC, ECOG performance status, 
tumor location and initial CEA level, were not different 
between tumors with BRAF wild-type and mutation. 
Treatment modalities in enrolled patients are summarized 
in Table 2. Ninety-three (75.6%) patients with BRAF wild-
type and nine (69.2%) with BRAF mutation received sur-
gery (P = 0.737). One hundred nineteen (96.7%) patients 
with BRAF wild-type and 11 (84.6%) with BRAF muta-
tion received chemotherapy (P = 0.182). Chemotherapy 
regimens and targeted agents were not significantly differ-
ent between the two groups. The mean ± SD follow-up 
duration in all patients was 21.5 ± 13.3 mo.
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BRAF wild-type
(n  = 123)
BRAF Mutant 
(n  = 13)
P  value
Sex Male/Female 74 (60.2)/49 (39.8) 6 (46.2)/7 (53.8) 0.329
Age (mean ± SD, age) 58.54 ± 12.91 61.08 ± 7.87 0.488
Age (< 60 yr)   60 (48.8)   5 (38.5) 0.479
BMI (mean ± SD, kg/m2) 22.77 ± 3.64 22.70 ± 3.31 0.950
Family history of colorectal 
cancer 
  25 (20.3) 1 (7.7) 0.462
ECOG performance status 0.421
   0-1 116 (94.3)   13 (100.0)
   2-3   7 (5.7) 0 (0.0)
Tumor type 0.871
   Colon   97 (78.9) 10 (76.9)
   Rectum   26 (21.1)   3 (23.1)
Tumor location 0.211
   Proximal   35 (28.5)   6 (46.2)
   Distal   88 (71.5)   7 (53.8)
Histology 0.111
   WD and MD 113 (91.9) 10 (76.9)
   PD and UD 10 (8.1)   3 (23.1)
AJCC tumor stage 0.370
   Stage Ⅲ   48 (39.0)   3 (23.1)
   ⅢA   5 (4.1) 1 (7.7)
   ⅢB   30 (24.4) 1 (7.7)
   ⅢC   13 (10.6) 1 (7.7)
   Stage Ⅳ   75 (61.0) 10 (76.9)
   ⅣA   27 (22.0)   3 (23.1)
   ⅣB   48 (39.0)   7 (53.8)
MSI 0.604
   MSS and MS-low 110 (89.4) 12 (92.3)
   MSI-high   5 (4.1) 0
   Unchecked   8 (6.5) 1 (7.7)
K-ras 0.033
   Wild   76 (61.8) 12 (92.3)
   Mutant   47 (38.2) 1 (7.7)
Initial CEA (mean ± SD, 
ng/mL)
251.41 ± 1520.96 14.29 ± 23.90 0.576
SD: Standard deviation; BMI: Body mass index; ECOG: Eastern Coopera-
tive Oncology Group; WD: Well differentiated; MD: Moderately differen-
tiated; PD: Poorly differentiated; UD: Undifferentiated; AJCC: American 
Joint Committee on Cancer; MSI: Microsatellite instability; MSS: Microsat-
ellite stable; CEA: Carcinoembryonic antigen.
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Table 3  Prognostic factors in colorectal cancer patients in 
multivariate analysis
Table 2  Treatment modality of the patients  n  (%)
Tumor response and survival according to BRAF 
mutation status
To determine the value of  BRAF mutation status as a 
prognostic marker, PFS and OS were compared between 
patients with BRAF wild-type and BRAF mutation (Fig-
ure 1). PFS was not statistically different between the 
two groups (BRAF wild type vs BRAF mutation, 10.1 
± 7.8 mo vs 7.2 ± 5.0 mo; P = 0.135). The OS was sig-
nificantly shorter in patients with BRAF mutation than 
those with BRAF wild-type (BRAF wild type vs BRAF 
mutation, 22.2 ± 13.2 mo vs 18.8 ± 13.6 mo; P = 0.041). 
In contrast to BRAF mutation, KRAS mutation status 
was not associated with PFS or OS in patients with stage 
Ⅲ/Ⅳ CRCs.
Univariate and multivariate analyses were performed 
to validate the prognostic factors for survival in patients 
with stage Ⅲ/Ⅳ CRC. Univariate analysis revealed that 
histology, tumor stage, surgery and BRAF status were 
significant prognostic factors for survival (P = 0.001, P 
< 0.001, P < 0.001 and P = 0.041, respectively). Multi-
variate analysis showed that TNM stage Ⅳ (HR = 3.183; 
95%CI: 1.517-6.679; P = 0.002), poor differentiation 
and lack of  differentiation in histology (HR = 2.821; 
95%CI: 1.378-5.776; P = 0.005), no surgery (HR = 3.694; 
95%CI: 1.972-6.918; P < 0.001) and BRAF mutation (HR 
= 2.195; 95%CI: 1.039-4.640; P = 0.039) were signifi-
cant poor prognostic factors for survival in patients with 
stage Ⅲ/Ⅳ CRC (Table 3).
DISCUSSION
This retrospective study demonstrated that stage Ⅲ or 
Ⅳ CRC in Korean patients have distinct molecular char-
acteristics, including exclusive mutations between KRAS 
and BRAF genes and a low incidence of  MSI-H. BRAF 
mutant tumors showed significantly shorter survival than 
BRAF wild-type tumors, while the KRAS mutation had 
no prognostic impact.
It has been reported that 10% to 20% of  CRCs have 
a BRAF mutation[3,22]. The BRAF mutation is associated 
with MSI-H through hMLH1 promoter hypermeth-
ylation, which is known to be associated with a high 
level of  CpG island methylator phenotype (CIMP)[11]. 
Several reports have revealed a low incidence of  BRAF 
mutations in CRC. Although it is not clear if  ethnic-
ity affects the status of  the BRAF mutation, previous 
studies with small sample sizes of  Koreans reported only 
3.8%-7% of  BRAF mutant CRCs in Korean patients[23,24]. 
A few studies showed that BRAF mutations were ex-
tremely uncommon in rectal cancer, with an incidence of  
0%-2%[25,26]. However, the present study indicated that 
the incidence of  BRAF mutation was not affected by 
ethnicity or tumor location. Although it is known that 
BRAF genes are exclusively mutated with KRAS genes, 
coincident mutations of  KRAS and BRAF rarely oc-
cur in CRC with an incidence of  0.001%[27]. Herein, we 
found that one case had both KRAS (G12V) and BRAF 
mutations. This patient was a 49-year-old male and had 
rectosigmoid junction cancer of  MSS type in MSI. It is 
not clear whether these tumors have a different biology 
and natural history than KRAS or BRAF only mutant 
tumors or which of  the two mutations is the dominant 
oncogene driving tumor proliferation because coinci-
dent KRAS and BRAF mutation were infrequently ob-
served[27].
The present study showed a small number of  MSI-H 
tumors compared to previous studies[5,28] and thus failed 
to demonstrate the relationship between MSI status and 
BRAF mutation. This may have been due to the ad-
vanced stage of  CRCs in the present study. Our previous 
study demonstrated that MSI-H tumors were strongly 
associated with early tumor stage, and only 6% of  stage 
Ⅲ/Ⅳ CRC had MSI-H tumors[29]. Compared with colon 
cancer, rectal cancer has a low incidence of  MSI-H tu-
mors and this may have affected the results of  the pres-
ent study[29].
CRC has significant clinical heterogeneity based 
on several molecular markers such as MSI, KRAS and 
BRAF[2-4]. It has been well documented that MSI-H 
tumors have a better prognosis than MSS/MSI-L tu-
mors[5,29]. In contrast, BRAF mutant tumors have a poor 
prognosis compared to BRAF wild-type tumors[6,7]. The 
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BRAF wild-type 
(n  = 123)
BRAF Mutant 
(n  = 13)
P  value
Surgery 0.737
   Yes   93 (75.6)   9 (69.2)
   No   30 (24.4)   4 (30.8)
Chemotherapy 
   Yes 119 (96.7) 11 (84.6)
   No   4 (3.3)   2 (15.4)
Chemotherapy regimen 0.441
 FOLFOX   97 (82.2)   9 (81.8)
   FOLFIRI   5 (4.2) 0
   FL   7 (5.9)   2 (15.4)
   Xeloda   8 (6.8) 0
   SOX   1 (0.8) 0
Target agent use 0.128
   No   91 (74.0)   8 (61.5)
   Bevacizumab   19 (15.4)   5 (38.5)
   Cetuximab   13 (10.6) 0
HR (95%CI) P  value
Age (older than 60 yr vs younger) 1.164 (0.682-1.984)    0.578
Sex (male vs female) 0.927 (0.541-1.586)    0.781
Tumor type (rectum vs colon) 0.931 (0.511-1.697)    0.816
Initial stage (stage Ⅳ vs Ⅲ) 3.183 (1.517-6.679)    0.002
Histology (PD and UD vs WD and MD) 2.821 (1.378-5.776)    0.005
Surgical treatment (no vs yes) 3.694 (1.972-6.918) < 0.001
BRAF mutation (mutant vs wild-type) 2.195 (1.039-4.640)    0.039
KRAS mutation (mutant vs wild-type) 1.305 (0.766-2.221)    0.327
CI: Confidence interval; PD: Poorly differentiated; UD: Undifferentiated; 
WD: Well differentiated; MD: Moderately differentiated; CEA: Carcinoem-
bryonic antigen.
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BRAF mutation has been used as a strong prognostic 
factor for overall survival in patients with CRCs, which 
was also confirmed in the present study. Thus, CRCs 
can be classified into four subtypes by these two distinct 
prognostic markers of  MSI status and BRAF muta-
tion[7]. MSS/BRAF mutant tumors are known to exhibit 
the worst prognosis, while MSI-H/BRAF wild-type tu-
mors have the best prognosis. MSI-H/BRAF mutant or 
MSS/BRAF wild-type tumors have been suggested as 
intermediate subtypes[7]. However, several recent studies 
suggested that the association of  BRAF mutation with 
poor prognosis is limited to MSS tumors[16,30]. Thus, fur-
ther studies are necessary to adapt this molecular clas-
sification for clinical practice.
This study has several limitations. First, a retrospec-
tive study design has inherent limitations. Second, be-
cause of  the small number of  MSI-H tumors, the pres-
ent study failed to evaluate the association of  BRAF mu-
tation with MSI status. Finally, even for advanced cancer, 
the follow-up period was relatively insufficient at a mean 
of  21 mo.
In conclusion, CRCs have distinct molecular features, 
including MSI status and mutations of  KRAS and BRAF. 
These molecular markers enable the classification of  
CRCs into meaningful subtypes for prognosis. Our data 
strongly support the prognostic role of  BRAF mutation 
in Korean patients with advanced CRC.
COMMENTS
Background
Approximately 10% of colorectal cancers (CRCs) have BRAF mutations and 
these CRCs have a worse prognosis than those with BRAF wild-type. In addi-
tion, the BRAF gene is thought to be closely associated with several molecular 
markers such as microsatellite instability (MSI) and KRAS in CRCs. However, 
although the prevalence of CRCs has rapidly increased in South Korea, the in-
cidence of BRAF mutation and its clinical meaning are unknown in Korean CRC 
patients.
Research frontiers
Recent advances in molecular genetics enable the classification of CRC by mo-
lecular markers, including MSI and KRAS and BRAF mutations, to predict prog-
nosis and treatment response. It is well known that CRCs with KRAS mutations 
respond poorly to cetuximab. However, the predictive role of BRAF mutations 
in cetuximab response is not clear. As for prognostic markers, MSI-high tumors 
have a better prognosis than MSS/MSI-low tumors. In contrast, CRC with BRAF 
mutations have a worse prognosis than those with BRAF wild-type, while KRAS 
mutations have no prognostic role. Future research should aim to uncover the 
role and purpose of molecular markers in CRC and to identify their potential us-
age clinically.
Innovations and breakthroughs
This study identified the clinicopathological features of CRC with a BRAF muta-
tion and its molecular interaction with MSI and KRAS targeting for stage Ⅲ/Ⅳ 
CRC.
Applications
Molecular markers such as BRAF, KRAS, MSI may be used to classify cases of 
colorectal carcinoma into subtypes for prognosis.
Terminology
BRAF: BRAF is a human gene that makes a protein called B-Raf. The gene is 
also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral onco-
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Figure 1  Progression-free survival and overall survival according to BRAF or KRAS mutation status. A: PFS was not significantly different by the BRAF muta-
tion status (p = 0.135); B: OS was significantly poorer in the BRAF mutant group than in the BRAF wild-type group (p = 0.041); PFS (C) and OS (D) were not signifi-
cantly different by the KRAS mutation status (p = 0.954 and p = 0.536, respectively). PFS: Progression-free survival; OS: Overall survival.
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gene homolog B1, while the protein is more formally known as serine/threonine-
protein kinase B-Raf. The B-Raf protein is involved in sending signals inside 
cells, which are involved in directing cell growth. KRAS: KRAS is a human gene 
that makes a protein called KRAS. Like other members of the Ras family, the 
KRAS protein is a GTPase and is an early player in many signal transduction 
pathways. The protein product of the normal KRAS gene performs an essential 
function in normal tissue signaling, and the mutation of a KRAS gene is an es-
sential step in the development of many cancers.
Peer review
The BRAF mutant tumors had a significantly shorter survival than that of BRAF 
wild-type tumors, while the KRAS mutation had no prognostic impact. These re-
sults are interesting and this finding allows these molecular markers to be used 
to classify cases of colorectal carcinoma into subtypes for prognosis.
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